Financials in USD. Standardized financial statements.
A compact view of how LexaGene Holdings Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $75,314 | $58,125 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +29.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $543,231 | $159,046 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | -$468,000 | -$101,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | -621.4% | -173.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $10.10M | $9.71M | $7.40M | $8.32M | $3.98M | $1.00M | $165,027 | $85,956 | $192,487 | $368,313 |
| Operating Income? | -$10.64M | -$9.82M | -$7.40M | -$8.32M | -$3.95M | -$1.00M | -$165,000 | -$85,956.776 | -$192,000 | -$368,000 |
| EBITDA? | -$10.05M | -$9.29M | -$6.89M | -$8.19M | -$3.93M | $2.50M | -$180,000 | -$86,399.274 | -$197,000 | -$201,000 |
| Income Before Tax | -$10.62M | -$9.89M | -$7.50M | -$8.32M | -$4.00M | -$4.48M | -$150,000 | -$85,514.277 | -$188,000 | -$536,000 |
| Income Tax Expense | -$18,179 | $74,743 | $101,524 | -$1,110 | $27,577 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$10.62M | -$9.97M | -$7.60M | -$8.32M | -$4.03M | -$4.48M | -$150,000 | -$85,514.277 | -$188,000 | -$536,000 |
| EPS? | $-0.09 | $-0.10 | $-0.10 | $-0.13 | $-0.08 | $-0.17 | $-0.02 | $-0.01 | $-0.21 | $-0.59 |
| Diluted EPS? | $-0.09 | $-0.10 | $-0.10 | $-0.13 | $-0.08 | $-0.17 | $-0.02 | $-0.01 | $-0.21 | $-0.59 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality